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Q fever is a disease of humans, caused by Coxiella 
burnetii, and a large range of animals can be infected. 
This paper presents a review of the epidemiology of Q 
fever in humans and farm animals between 1982 and 
2010, using case studies from four European countries 
(Bulgaria, France, Germany and the Netherlands). The 
Netherlands had a large outbreak between 2007 and 
2010, and the other countries a history of Q fever and 
Q fever research. Within all four countries, the sero-
logical prevalence of C. burnetii infection and reported 
incidence of Q fever varies broadly in both farm ani-
mals and humans. Proximity to farm animals and con-
tact with infected animals or their birth products have 
been identified as the most important risk factors for 
human disease. Intrinsic farm factors, such as produc-
tion systems and management, influence the number 
of outbreaks in an area. A number of disease con-
trol options have been used in these four countries, 
including measures to increase diagnostic accuracy 
and general awareness, and actions to reduce spill-
over (of infection from farm animals to humans) and 
human exposure. This study highlights gaps in knowl-
edge, and future research needs.
Introduction
Q fever is a disease of humans [1,2]. The aetiological 
agent, Coxiella burnetii, is a Gram-negative and obli-
gate intracellular bacterium. C. burnetti has also been 
isolated from a large range of animals including farm 
animals (e.g. cattle, sheep and goats), wildlife and 
arthropods [3]. It has a near worldwide distribution.
The febrile illness ‘Query fever’ (Q fever) was first 
reported in 1935, among workers in slaughterhouses 
in Australia [4]. Initial hypotheses about potential 
exposures and infectious pathways emerged follow-
ing the development of illness in experimental ani-
mals (guinea pigs) via feeding of ticks [5] collected 
from febrile livestock in Nine Mile, United States. 
Investigations into cases of atypical pneumonia subse-
quently revealed the importance of aerosol transmis-
sion. Epidemiological linkages with animals were later 
identified, and infection was found in a broad range 
of hosts [1,3]. It was initially thought that Q fever was 
primarily an occupational risk (for people who worked 
closely with animals) however this was subsequently 
expanded, with risk groups also including people with 
a specific health status (pregnancy, cardiac diseases, 
immune-compromised). Blood donation was identified 
as a potential source of infection. 
In Europe, cases of Q fever in humans were first 
reported from soldiers in the Balkan region including 
Bulgaria in 1940 [6], and subsequently in Germany 
shortly after World War II [2], and in the Netherlands 
in 1956 [7].
The course of human infection ranges from asympto-
matic to severe, but typically results in a mild, self-lim-
iting, influenza-like disease (acute infection). However, 
some patients develop a more serious chronic infec-
tion, including endocarditis and other complicated 
infections (e.g. vascular or osteoarticular infections). 
Infection by C. burnetti in pregnancy can also result in 
spontaneous abortion, premature delivery, low birth 
weight and the development of chronic C. burnetti 
infection [8]. The European Union (EU) harmonised 
Q fever case definition , in use since the year 2003, 
includes clinical (any person with at least one of the fol-
lowing three symptoms: fever, pneumonia, hepatitis), 
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laboratory (at least one of the following three diagnos-
tic findings: isolation of C. burnetii from a clinical spec-
imen, detection of C. burnetii nucleic acid in a clinical 
specimen, C. burnetii specific antibody response (IgG 
or IgM phase II)) and epidemiological (at least one of 
the following two epidemiological links: exposure to a 
common source, animal-to-human transmission) crite-
ria [9].
In domestic ruminants, as in people, C. burnetti infec-
tion and Q fever (the disease) are not the same. C. bur-
netti infection is usually subclinical (i.e. the animal is 
infected with C. burnetii but without clinical signs). Q 
fever, which develops in a subset of infected animals, 
presents as late abortion and reproductive disorders 
[1,2,10,11]. A definitive diagnosis of Q fever in animals 
is based on the observation of the occurrence of abor-
tions and/or stillbirths, confirmation of the presence of 
the aetiological agent (i.e. polymerase chain reaction 
(PCR), isolation, staining, immunofluorescence assay 
tests are positive) and positive serological findings in 
the herd [12].
Q fever has generally been associated with transient 
outbreaks in animals and humans, and sporadic 
human cases. Prompted by the outbreak of Q fever in 
the Netherlands that occurred from 2007 to 2010, con-
cerns were raised by the European Commission about 
factors contributing to the development of large, sus-
tained Q fever outbreaks [2]. The Dutch outbreak was 
considered to be the largest community outbreak ever 
recorded [2,13,14], with 4,026 human cases notified 
between 2007 and 2010 [15-17].
This paper presents a descriptive analysis, comparison 
and critical appraisal of the epidemiology of Q fever in 
humans and farm animals, including modes of trans-
mission and control measures, using case studies from 
four European countries: Bulgaria, France, Germany 
and the Netherlands.
Methods
This study was conducted as a review of Q fever epi-
demiology in four European countries. These coun-
tries were chosen by experts of a working group of the 
European Food Safety Authority (EFSA) [2]. The EFSA 
working group comprised a group of scientists with 
specialised knowledge and experience on Q fever-
related issues, who were assembled to collectively 
formulate a response to a range of risk-related ques-
tions posed by the European Commission. The four 
countries were chosen based on the following ration-
ale: the Netherlands experienced a large Q fever out-
break between 2007 and 2010, France and Germany 
are countries in proximity to the Netherlands where Q 
fever is endemic and where a considerable number of 
relevant scientific data and publications are available, 
and Bulgaria is a country with both a long history of 
Q fever and, as in the Netherlands, with substantial 
changes in husbandry systems over time. For each 
of these four countries, information was collected 
on Q fever in humans and farm animals based on a 
detailed review of relevant peer reviewed and non-peer 
reviewed literature. Relevant literature was identified 
following interrogation of two publication databases, 
ISI Web of Knowledge and PubMed, using defined qual-
ifiers for infection and disease (C. burnetii infection, Q 
fever), host (humans, farm animals), location (Bulgaria, 
France, Germany and the Netherlands)) and issue (epi-
demiology, diagnostics, control, review). The search 
was limited to literature published from 2005 to 2010, 
but relating to the period from 1982 to 2010. Additional 
national literature (both peer reviewed and non-peer 
reviewed) was obtained by working group members, 
and complemented with their expert knowledge and 
opinion, noting that EFSA working group included 
national experts on these issues from Bulgaria, France, 
Germany  and the Netherlands [2]. Screening of pub-
lished material was initially conducted by two review-
ers of the working group, based on title and abstract, 
leading, if relevant to the above-mentioned qualifiers, 
to retrieval of the full paper for consideration in the 
current review and details available elsewhere [2]. A 
descriptive analysis was subsequently conducted. 
Results
A total of 110 papers were retrieved, based on title 
and abstract, with 22 being retained, following further 
evaluation, for the current review.
Farm animals
Seroprevalence
The serological prevalence of C. burnetii infection in 
farm animals varies by host species, geographic area 
and time (Table 1), whereby it also should be noted that 
different serological cut-offs were used in different 
studies. Within-herd prevalence estimates for cattle 
were up to 20.8% in Bulgaria, 15.0% in France, 19.3% 
in Germany,, 21.0% in the Netherlands, for goats up to 
40.0% in Bulgaria, 88.1% in France, 2.5% in Germany, 
7.8% in the Netherlands, and for sheep up to 56.9% 
in Bulgaria, 20.0% in France, 8.7% in Germany, 3.5% 
in the Netherlands respectively. Herd prevalence esti-
mates, whereby a herd is considered positive when 
at least one animal in the herd was serologically-
confirmed, were higher than within-herd prevalence. 
Herd prevalence for cattle was up to 73.0%, in France, 
and up to 37.0 % in the Netherlands. For goats it was 
40.0% in France and 17.8% in the Netherlands while 
for sheep values of 89.0% in France, and 14.5% in the 
Netherlands were respectively found. Regional differ-
ences were observed: up to four-fold among farm ani-
mals in different areas of Bulgaria [18], and higher in 
some rural German regions [19-21]. 
Clinical disease
Estimating the Q fever incidence in farm animals is dif-
ficult, due to the non-specific nature of disease on the 
one hand and the multifactorial nature of abortion on 
the other. Further, it is uncommon for detailed veteri-
nary investigations to occur, including efforts towards 
3www.eurosurveillance.org
Table 1
Estimated prevalence of Coxiella burnetii infection in farm animals, based on studies conducted in Bulgaria, France, 
Germany and the Netherlands, 1982–2010
Country Year of study
Number tested % positive
Test Reference
Animals Herds Animals Herds
Cattle
BG 1977–1988 20,086 NA 11.8 NA CFT [23]
BG 1989–2006 95,737 NA 5.4 NA CFT [23]
BG 2002 3,006 NA 8.2 NA CFT [23]
BG 2003 3,714 NA 6.5 NA CFT [23]
BG 2004 120 NA 20.8a NA IFA [32] 
BG 2004 3,188 NA 9.7 NA CFT [23]
BG 2005 3,026 NA 8.1 NA CFT [23]
BG 2006 2,932 NA 10.6 NA CFT [23]
DE 1991 1,095 21 11.8 81.0 ELISA [75]
DE 1992–1993
500
665
383b
612
NA
39
33
1
7.6
9.6
19.3
5.6
NA
76.9
78.8
100.0
CFT [76]
DE 1998 21,196 544 8.0 NA ELISA [1]
DE 1996–1997 826 38 14.3b NA ELISA [77]
DE 1998–2000 1,167 105 1.4–2.0b NA ELISA [78] 
FR NA NA NA 1.0–15.0 39–73 NA [79]
NL 1987 1,160b 234 21.0 37.0 ELISA [80] 
NL 2007 2,781c 341 16.0 78.6 ELISA [69]
NL 2007 2,781c 341 8.7 56.6 PCR [69]
Goats
BG 2002 677 NA 11.8 NA CFT [23]
BG 2003 1,044 NA 7.4 NA CFT [23]
BG 2004 50 NA 40.0a NA IFA [32] 
BG 2004 1,016 NA 21.7 NA CFT [23]
BG 2005 832 NA 11.1 NA CFT [23]
BG 2006 359 NA 19.2 NA CFT [23]
BG 1950–1976 1,417 NA 20.5 NA CFT [23] 
BG 1977–1988 1,791 NA 10.8 NA CFT [23]
BG 1989–2006 54,175 NA 7.6 NA CFT [23]
FR 2006 359 NA 36.0 NA ELISA [81]
FR 2006 NA 42 88.1 NA ELISA [81]
FR 2006 75 NA 65.3b NA ELISA [82]
FR 2008 1,057 NA 32.0 NA ELISA [81]
FR 2008 42 NA 88.1 NA ELISA [81]
FR NA NA NA 2.0–12.0 10–40.0 NA [79]
DE 1998 278 NA 2.5 NA ELISA [1]
NL 1987 498 NA 1.0 NA ELISA [80]
NL 2008 3,409 NA 7.8 NA ELISA [15]
NL 2008 NA NA 7.8 17.8 NA [13]
Sheep
BG 2002 1,819 NA 12.7 NA CFT [23]
BG 2003 1,811 NA 8.3 NA CFT [23]
BG 2004 100 NA 21.0a NA IFA [32] 
BG 2004 1,258 NA 14.1 NA CFT [23]
BG 2005 1,911 NA 15.2 NA CFT [23]
BG 2006 1,925 NA 8.4 NA CFT [23]
BG 1950–1976 17,088 NA 16.7 NA CFT [23]
BG 1977–1988 16,593 NA 18.8 NA CFT [23]
BG 1989–2006 99,189 NA 4.8 NA CFT [23]
BG NA–2006 153 NA 56.9b NA CFT [62]
DE NA NA 95 NA 2.7 NA [83] 
DE 1983–1986 4,337 NA 0.6–4.3 NA CFT [40] 
DE 1998 1,346 NA 1.3 NA ELISA [1]
DE 1999 100 1 57.0 NA ELISA [1]
DE NA 3,460 NA 8.7 NA ELISA [84]
FR NA NA NA 0–20.0 0–89.0 NA [79]
NL 1987 3,603 NA 3.5 NA ELISA [80]
NL 2008 12,363 NA 2.4 NA ELISA [15]
NL 2008 NA NA 2.4 14.5 NA [13]
BG: Bulgaria; CFT: complement fixation test; DE: Germany; ELISA: enzyme-linked immunosorbent assay; FR: France; IFA: indirect 
immunofluorescence assay; NA: information not available or not specified; NL: Netherlands; PCR: polymerase chain reaction.
a Investigation in relation to a human outbreak.
b Investigation in relation to clinical signs in the animal population.
c Lactating cows.
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laboratory confirmation of the causative agent, follow-
ing a single abortion in a herd or flock. During the out-
break in the Netherlands between 2007 and 2010, an 
average of 20% (range of 10–80%) of pregnant goats 
aborted on affected farms. On two affected sheep 
farms in the Netherlands, the estimated abortion rate 
was 5% [13,15]. From 0.5 to 3.8% of abortions in cat-
tle were attributed to C. burnetii in surveys in Germany 
during the period from 1993 to 1996 [2]. Clinical dis-
ease (with abortions attributed to C. burnetii infec-
tion) in five of 21 goat flocks were observed over 
five years in Deux-Sevres, France [22]. The disease is 
well recognised among the veterinary community in 
all four countries, and it has been notifiable in dairy 
sheep and goats at EU level in Bulgaria, Germany and 
the Netherlands since 2008. This was not the case in 
France [2], which may have an influence on the number 
of cases being reported. 
Humans
Seroprevalence
Estimates of prevalence of C. burnetii infection, based 
on serological studies conducted in the four countries 
since 1982, are presented in Table 2. It should be noted 
that different serological cut-offs were used in differ-
ent studies. There is large variability in the overall 
seroprevalence in the sampled population groups: in 
the general population, 2.4% in the Netherlands; 
among blood donors, 1.0 to 4.0% in France, 12.2 to 
24.0% in the Netherlands, 22.0% in Germany and 
38.0% in Bulgaria; in risk groups 15.0 to 18.0% in 
Bulgaria (patients presenting with atypical pneumo-
nia and cardio-vascular diseases), 2.6 to 71.0% in 
France (pregnant woman, patients with cardiac dis-
eases, persons involved in goat breeding, veterinar-
ians; seroprevalence was highest among the latter two 
groups), 83.8% in the Netherlands (veterinarians deal-
ing with livestock); in humans in outbreak areas, 7.7% 
in Bulgaria (pregnant women), 9.1% in the Netherlands 
(pregnant women), 14.7% in France (post epidemic sur-
veillance in outbreak areas among people not consid-
ered at higher than normal risk) and 22.0% in Germany 
(farmers whose livestock experienced abortions).
Clinical disease
 In all four countries, Q fever varies considerably in 
terms of geographic distribution, case numbers and 
clinical presentation. Disease was notifiable in humans 
at the national level throughout the full study period 
(1982–2010) in Bulgaria, Germany and the Netherlands 
and not in France. Since 2000, Q fever in humans must 
be monitored and notified within the EU, as required 
under EU legislation (Commission Decision 2000/96/
Table 2
Estimated prevalence of Coxiella burnetii infection in people, based on studies conducted in Bulgaria, France, Germany and 
the Netherlands, 1982–2010
Country Year of study Number tested Sample group % positive Test Reference
BG 1993–2000 14,353 RG 15.0 CFT, MIFT [23]
BG 1995–1997 224 BD 38.0 MAT, MIFT [29]
BG 2001–2004 5,207 RG 18.0 CFT, MIFT [23]
BG 2004 104 HO (PW) 7.7 IFA [32]
DE 2002 255 HO 22.0 NA [78]
FR 1982–1990 22,496 RG 23.0 NA [8]
FR 1988 924 BD 4.0 IFA [85]
FR 1995 790 BD 1.0 IFA [1]
FR 1995–1996 785 NA 5.0 IFA [1]
FR 1996 620 BD 3.0 IFA [1]
FR 1996 12,716 NA 0.2 IFA [1]
FR 1996 208 RG 71.0 IFA [86]
FR 2002–2003 376 RG (PW) 2.6 IFA [87]
FR 2002–2003 91 RG (CA) 5.5 IFA [87]
FR 2002–2003 578 HO 14.7 IFA [87]
NL 1982 222 RG 83.8 NA [88] 
NL 1983 359 BD 24.0 NA [88] 
NL 2006–2007 5,654 GP 2.4 ELISA, IFA [89]
NL 2007–2009 2,004 HO (PW) 9.1 IFA [90]
NL 2009 543 BD 12.2 ELISA, IFA [91]
BD: blood donors; BG: Bulgaria; CA: cardiac abnormalities; CFT: complement fixation test; DE: Germany; ELISA: enzyme-linked 
immunosorbent assay; FR: France; GP: general population; HO: humans in outbreak areas; IFA: indirect immunofluorescence assay; MAT: 
microagglutination test; MIFT: microimmunofluorescence test; NA: information not available or not specified; NL: Netherlands; PW: pregnant 
women; RG: risk group.
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Table 3
Reported Q fever outbreaks in the human population in Bulgaria, France, Germany and the Netherlands, 1982–2010
Country: region Year Most likely source Number of cases Laboratory diagnosis Reference(s)
DE (former GDR): Suhl, Thuringia 1982–1983 Ruminants 156 CFT [92][40]
BG: Knezja, Brenitza, Lazarovo, Enitza 
(Vratza district) 1984 Ruminants 725 CFT [23]
BG: Pavlikeni (Veliko Tarnovo district) 1985 Ruminants 544 CFT [23]
FR: (Martigues, Bouches du Rhône) 1990–1995 Sheep 289 IFA [1]
DE: Berlin 1992 Sheep 80 CFT [93,94]
BG: Panagjuriste (Pazardjik district) 1992–1995 Livestock >1,000 CFT
[23] (for 1993); 
[29] (for 1992, 
1993 and 1995)
DE: Düsseldorf, Nordrhine-Westphalia 1994 Sheep >18 CFT [95]
BG: Sopot (Plovdiv district), Troyan 
(Lovech district), Blagoevgrad, Pleven 1996–2000 Livestock NA CFT [23]
FR: Briançon (Hautes Alpes) 1996 Sheep 29 IFA [1]
DE: Rollshausen, county of Lohra, Hesse 1996 Sheep 56 ELISA [96,97] 
DE: Baden-Württemberg, not specified 1997 Fallow deer 12 NA [37]
DE: Dortmund, Nordrhine-Westphalia 1999 Sheep (manure) 82 NA [1]
FR: Montoison (Drôme) 2000 Goat (manure) 10 NA [1]
FR: Montoison (Drôme) 2000 Sheep (manure) 5 IFA [1]
DE: Hochsauerlandkreis Nordrhine-
Westphalia, Waldeck-Franckenberg, Hesse 2000–2001 Sheep 75 NA [98]
DE: Munich, Bavaria 2001 Sheep 3 NA [98]
BG: Etropole (Sofia district) 2002 Livestock 121 CFT [23]
FR: Chamonix Valley 2002 Sheep 88 IFA [1]
DE: Soest, Nordrhine-Westphalia 2003 Sheep 299 ELISA [99]
DE: Baden-Württemberg 2003 Cattle 8 NA [100]
BG: Botevgrad (Sofia district) 2004 Sheep, goats 220 IFA, CFT [32][23]
DE: Jena, Thuringia 2005 Sheep 331 ELISA [101]
NL: mainly Noord-Brabant, Limburg, 
Gelderland, NL 2007–10 Dairy goats 4,026
a IFA, CFT, ELISA, 
PCR [14-17]
FR: Florac 2007 Sheep 18 NA [25]
FR: Hautes-Alpes 2008 Livestock 12 IFA [26]
DE: Lahn-Dill-Kreis, Hesse 2008 Sheep >46 NA [102,103]
DE: Aschaffenburg, Bavaria 2008 Sheep >56 NA [102]
DE: Paderborn, Westphalia 2009 Sheep 5 NA [104]
DE: Baden-Würtemberg 2010 NA 235 NA [2] 
BG: Bulgaria; CFT: complement fixation test; DE: Germany; ELISA: enzyme-linked immune-sorbent assay; FR: France; GDR: German Democratic 
Republic; IFA: indirect immunofluorescence assay; NA: Information not available or not specified; NL: Netherlands; PCR: Polymerase chain 
reaction.
a Includes 168 in 2007, 1,000 in 2008, 2,354 in 2009 and 504 in 2010.
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EC, as amended by Decision 2003/534/EC). Earlier 
reports of sporadic cases and outbreaks in these coun-
tries are available (Table 3).
During the period from 1984 to 2006, the number of 
serologically confirmed cases per outbreak varied 
between 121 and more than 1,000 in Bulgaria [23]. 
Outbreaks in Bulgaria have occurred in various geo-
graphic areas (including Knezja, Sopot, Etropole, 
Troyan, Botevgrad) and over several years in a single 
area (e.g. Panagyurische) (Table 3).
The average annual incidence of Q fever in Germany 
during 1979 to 1999 was estimated to be 1.1 (0.8–4.1) 
per million [19]. An estimated total of 200 to 400 human 
cases were registered as sporadic cases or outbreaks 
each year from 2007 to 2009 in Germany in the regions 
of Jena (Thuringia), Göppingen (Baden-Württemberg), 
Lahn-Dill Kreis (Hesse) and Aschaffenburg (Bavaria), 
and most frequently from Baden-Württemberg, Hesse 
and Bavaria [24]. During the period from 2004 to 
2009, no significant increase in the number of cases 
was seen in North Rhine-Westphalia or Lower Saxony, 
which neighbour the Netherlands.
In the period from 1990 to 1995, an outbreak of Q fever 
was reported in France (Martigues, near Marseille and 
Aix-en-Provence, Bouches du Rhône), with 289 human 
cases [1]. A further 29 cases were reported (Briançon, 
Hautes Alpes) in 1996 and 15 (Montoison, Drôme) in 
2000 [1]. Subsequently, outbreaks have been reported 
in the Chamonix valley, Haute Savoie in 2002, with 
88 human cases [1], in Florac, Lozère in 2007, with 18 
cases [25] and in Hautes-Alpes in 2008, with 12 cases 
[26] (Table 3).
In the Netherlands, annual notifications ranged 
between one and 32 human cases between 1978 and 
2006, with the majority of cases occurring among 
people with occupational risk (e.g. persons in close 
contact with farmed animals, including farmers and 
veterinarians). From May 2007, however, there was a 
considerable increase in notification of human Q fever 
cases in the province of Noord-Brabant [27]. C. bur-
netii infection was identified in more than 160 patients 
presenting during May and June 2007 [14,16,17,28]. In 
2008, 1,000 human cases were identified, with a hos-
pitalisation rate of 20.9% [16]. In 2009, 2,354 new Q 
fever cases were registered in the national infectious 
disease notification database, with a hospitalisation 
rate of 19.7%, comparable to the situation in 2008 [16]. 
In 2010, 504 cases were notified, of which 406 had a 
known day of onset of illness in 2010, indicating that 
the peak of the epidemic had been reached in 2009. In 
this epidemic, most cases were found in the province 
of Noord-Brabant (Table 3). 
Potential risk factors
Proximity to infected animals
Animal proximity and contact with infected animals 
and/or their contaminated products (e.g. birth prod-
ucts) have been identified as important risk factors 
for humans in each of the four countries. In most out-
breaks, there are reports of spill-over of infection to 
humans from infected domestic small ruminants, i.e. 
goats [29,30] or sheep [31]. In contrast, there is no evi-
dence in support of a major contribution of cattle in the 
history of Q fever in humans in the four study countries. 
In the Netherlands, living close (<2 km) to a large dairy 
goat farm where an abortion wave due to C. burnetii had 
occurred was identified as the most important risk fac-
tor for human Q fever [30]. The movement of domestic 
small ruminants through settlements has been linked 
with a number of outbreaks in Bulgaria (Botevgrad 
in 2004 [32], Panagyurische in 1992, 1993 and 1995, 
Kneyzha in 1984 and Pavlikeni in 1985 [29]) and France 
(Chamonix valley [33]). Sheep shearing is considered 
an important risk factor in Germany. Infected tick fae-
ces is present in the wool, leading to contamination of 
dust, and the potential for further spread of the agent 
through storms and winds [19,31,34]. In some human 
outbreaks, involvement of other host species has been 
noted, e.g. contact with contaminated pigeon faeces 
[35], cats [36] or fallow deer [37].
The outbreaks in Germany and the Netherlands have 
been associated with urban areas. A large human 
Q fever cluster in an urban area in the Netherlands 
in 2008 was clearly linked to a dairy goat farm with 
more than 400 adult goats. On this farm, an abortion 
wave due to C. burnetii was confirmed, starting a few 
weeks before the first human cases were seen [30]. In 
Bulgaria, a number of human outbreaks have involved 
people without any known occupational hazards, such 
as employment or place of residence, with agricul-
ture or the processing of animal products [30]. In the 
Botevgrad outbreak, most patients had no association 
with goats, sheep or cattle [2]. Proximity should not be 
seen in isolation, since the geography and landscape 
may also play a role in the spread of infection [38]. 
In Bulgaria, France, and Germany, most of the recent 
25 outbreaks have occurred in small towns located 
in valleys close to mountains or semi-mountainous 
areas with meadows or in regions with specific cli-
matic conditions, in particular dry, windy weather, in 
Bulgaria (Panagyurische, Sopot, Troyan, Etropole), 
France (Chamonix valley, Florac) and in Germany (Jena, 
Thuringia; Göppingen, Baden-Württemberg; Lahn-Dill 
Kreis, Hesse; Aschaffenburg, Bavaria). The outbreak in 
the Netherlands contrasts with the geographical fea-
tures being described here although dry windy weather 
conditions may have facilitated the spread of the bac-
terium [13]. 
Management of the farms and husbandry practices
 Intrinsic farm factors, such as production system and 
management, are believed to influence the number of 
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outbreaks in an area. In the Netherlands, the intro-
duction of a milk quota system for dairy cattle in 1984 
stimulated the development of a dairy goat industry. 
This subsequently led to an increased number of mod-
ern dairy goat farms, many in areas of high human 
population density, with high numbers of dairy goats 
on a single farm. In Germany, the production system 
for sheep meat changed to meet the seasonal demand 
for mutton. The introduction of new methods of pro-
duction and synchronisation coincided with peaks of 
human infections during lambing seasons in spring 
when sheep flocks were released from winter stables. 
Since the 1950s, there have been substantial changes 
in livestock production systems in Bulgaria, from 
extensive systems to industrial systems and develop-
ment of small farms [23,39], leading to a substantial 
reduction in sheep (8 million in 1990, 3 million in 1997) 
and an increase in goats (430,000 in 1990, 1 million in 
1997) [29]. Although C. burnetii seroprevalence in farm 
animals has decreased in Bulgaria in the 2000s com-
paring with the 1970s and 1980s [23], the prevalence of 
infection in human risk groups has remained relatively 
constant (Table 2). Since 1990, there has been a shift in 
the seasonal presentation of human cases in Bulgaria, 
concurrent with changes in the seasonal pattern of 
parturition in goats and sheep [29]. In Bulgaria, cattle 
herds and sheep flocks tend to be large but are kept 
separately from the human population, whereas goats 
are present as multiple small herds within towns. An 
association between the number of positive animals 
in a herd and poor management (e.g. introduction of 
rams of unknown health status for mating, purchase 
of females of unknown health status, no removing of 
afterbirth) was noted in Germany [40].
Potential reservoirs of infection in nature 
 The presence of a natural reservoir in the environment 
or in wildlife, and spill-over to farm animals, are often 
considered pre-requisites for endemicity of Q fever in 
a geographic region. Based on seroprevalence and/
or strain isolation, there is evidence of C. burnetii 
infection in a wide variety of host species (domestic 
livestock, domestic pets, wild mammals, birds and 
ticks) [23,37,41]. Evidence of C. burnetii infection has 
been found in domestic dogs (seroprevalence of 13%) 
and cats (26%) in Germany in a study in 1987 [41]. In 
Bulgaria, 16.8% of ixodic ticks collected between 1993 
and 2004 were found to be positive by immunofluores-
cent haemocytic test [20], and 22 to 26% using other 
methods [42]. In contrast, low levels of C. burnetii DNA 
in ticks collected between 2006 and2007 have been 
reported for Thuringia in Germany [43]. Between 2006 
and 2010, approximately 3,000 ticks (1,891 questing 
Ixodes ricinus and 1,086 ticks feeding on pets, wildlife 
and livestock) were tested for the presence of C. bur-
netii DNA in the Netherlands [44]. All ticks were nega-
tive, even from high Q fever incidence areas. Only five 
ticks from one sheep herd tested Coxiella-positive and 
herd was not detected positive after resampling three 
months later.
Control options
In each of the four countries considered in this review, 
a range of measures were taken by the competent 
authorities in response to the disease, as follows:
Measures to increase diagnostic 
precision and general awareness:
 In the Netherlands, the capability for diagnosis of 
human Q fever had increased substantially in 2008 
and 2009, as compared to 2007, the first year of the 
epidemic [14,16]. Increasing familiarity with the pres-
entation of Q fever in people resulted in more-rapid 
diagnosis of clinical cases and a lower percentage of 
hospital admissions. The government-funded Q fever 
network in Germany [45] was able to transfer diagnos-
tic capability, including cultivation techniques, to two 
human medical laboratories to address an important 
gap in diagnostic capability. This network was initi-
ated to promote epidemiological work to identify the 
risks of Q fever for public health, to develop reason-
able counter-measures, to conduct basic research and 
to raise public awareness. The network relies on a ‘One 
Health’ approach among physicians, veterinarians, epi-
demiologists and software developers. Further, efforts 
have been made to increase case notification (both in 
humans and farm animals) and to increase awareness 
among medical doctors, veterinarians and the broader 
public, with greater emphasis on timely hospitalisation 
of patients and optimised medication to reduce life 
threatening sequelae. Case–control studies and inten-
sive testing carried out during and after the outbreaks 
in France in 2002 [33] and 2007 [25], and in Bulgaria in 
2004 [32], provided more detailed information on the 
status of affected areas and increased general aware-
ness about the disease.
Measures to reduce human exposure 
and to reduce spill-over: 
A range of temporary ad hoc measures have been 
used including restrictions on visits to infected farms 
(the Netherlands during 2007–2010 [2,13-15]), limits 
to human assembly in high-risk areas [2,32] includ-
ing the closing of schools in Bulgaria during an out-
break in 2004 [32], the stopping of blood donation 
in affected areas (France in 2002 and 2007, Germany 
2005) [25,31,33], the removal of infected herds/flocks 
from human settlements (in Bulgaria during 2004) 
[32], and the introduction of a ban on animal move-
ments (all four countries). Further, good farming prac-
tice is recommended, as long term universal measures, 
particularly for manure [2,13,15,46,47], such as cover-
ing and natural composting or ploughing of manure 
so that no aerosolisation of agents is possible, closed 
composting with CaO (in the Netherlands) [46,47] or 
CaCN2 (in France and Germany) [48], and the removal of 
animal birth and abortion products (all four countries). 
Other measures have included disinfection of infected 
premises including paths and general environment of 
holdings (Bulgaria during 2004) [32], obligatory noti-
fication of increased farm animal abortion rate to the 
local authorities (France, the Netherlands) [2,12,13], the 
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potential use of veterinary vaccines (France 2009, the 
Netherlands 2007–2010) [13,49,50] and the implemen-
tation of a farm animal breeding ban (the Netherlands 
2007–2010 [2,13]).
In the Dutch outbreak between 2007 and 2010, several 
counter-measures were introduced, following consid-
eration of both national and international (including 
EFSA) expert opinion. These measures included the 
development of notification criteria after which Q fever 
became a notifiable disease in farmed animals, a ban 
on animal transport especially from infected farms, 
visitor bans on infected farms, the promotion of gen-
eral hygiene measures, the implementation of a safe 
manure management including prevention of aerosoli-
sation, the introduction of a farm animal vaccination 
programme for small ruminants, testing of bulk milk 
(milk collected in large quantities from different dairy 
animals) using a PCR to identify infected herds, and 
breeding restrictions. The vaccination programme was 
initiated in October 2008, following special dispen-
sation of a phase I Q fever vaccine (Coxevac, CEVA), 
through a voluntary scheme involving dairy sheep 
and dairy goats on farms with more than 50 goats or 
sheep, pet zoos and nursing farms in a restricted high-
risk zone, an area with radius 45 km around the city 
of Udden. At that time, vaccination was restricted to a 
limited area, due to a shortage of vaccine. A manda-
tory vaccination programme was subsequently intro-
duced in an enlarged area including the province of 
Noord-Brabant, leading to vaccination of dairy sheep 
and dairy goats prior to 1 January 2010 on farms with 
more than 50 animals, and on care farms, pet zoos 
and zoos. Nationwide mandatory vaccination coverage 
was achieved in 2011, and also included small rumi-
nants attending shows [2]. Culling of more than 50,000 
pregnant animals aiming at reducing the shedding of 
C. brunetii and as a consequence of that, environmen-
tal contamination trying to reduce human exposure in 
2010, was undertaken on PCR bulk tank milk positive 
farms followed by a programme of repopulation with 
fully vaccinated animals originating only from PCR bulk 
tank milk negative farms. Compensation schemes were 
available for the farmers when culling was ordered 
[13,51]. In the Netherlands, a human vaccine (the 
Australian human vaccine Q-VAX, currently not regis-
tered in Europe) was made available in July 2010 to peo-
ple at risk from chronic Q fever, such as patients with 
cardiac valve disease, aortic aneurisms, and vascular 
prostheses [52]. The human vaccination programme 
commenced in January 2011, after the Q fever outbreak 
in the Netherlands had subsided [14].
Discussion
This review presents information on the presence of 
C. burnetii during the period from 1982 to 2010 in 
countries of Europe that differ greatly in terms of ani-
mal and human population, livestock density and pro-
duction systems. The regional presentation of Q fever 
varies considerably, based on several data sources. 
Non-standardised serological data are available about 
the presence of C. burnetii in various domestic animal 
species and wildlife. In addition, severe human out-
breaks or epidemic waves have also been described. 
Information from these four countries illustrates 
the epidemiological variability of human outbreaks 
and the considerable range of risk factors involved. 
Nevertheless, some general patterns emerge which are 
discussed below, together with areas of uncertainty 
where further research is justified.
Domestic ruminants are considered the primary reser-
voir for C. burnetii [1,53]. Human cases and outbreaks 
are attributed to infection in sheep (in Germany) and 
goats (Bulgaria, France, the Netherlands), but not cat-
tle. We found no evidence in support of a major contri-
bution of cattle in the history of Q fever in the four study 
countries, even though C. burnetii infection can also 
lead to shedding and abortion in cattle [54]. Abortion 
in cattle is a less prominent feature of infection com-
pared to sheep and goats [1,49,55]. We speculate that 
the prominent role of sheep and goats as reservoirs of 
infection during human outbreaks may be related to 
the highly seasonal nature of their reproduction cycle, 
to the larger herd sizes in these species, to differences 
in management and housing between these species, to 
the relative importance of shedding and abortions after 
C. burnetii infection, and possibly to species-related 
differences in the virulence for humans of C. burnetii. 
Abortions in C. burnetii-infected domestic ruminants 
are accompanied by massive excretion of the bacte-
ria and spread into the environment. This is the most 
important excretion route of C. burnetii, as up to 109 
organisms are excreted per gram of placenta tissue 
[56]. The level of excretion is believed less following 
the birth of healthy calves, kids or lambs from infected 
animals [48]. C. burnetii has also been detected in 
faeces, vaginal mucus and milk of infected domestic 
ruminants [57,58]. In goat herds, in both aborting and 
non-aborting goats, C. burnetii DNA has been detected 
in faeces, vaginal mucus and/or milk [58]. Also, in cat-
tle, variable excretion via faeces, vaginal mucus and 
milk has been reported, sometimes independent of 
an abortion history. Sixty-five per cent of cows seem 
to shed C. burnetii by only one of these routes, with 
few cows excreting C. burnetii by all three routes [55]. 
Comparison of the three excretion routes in cattle, 
goats and sheep showed that milk shedding is more 
frequent in cattle and goats. Ewes shed more and for a 
longer duration in vaginal mucus than goats [1]. Sheep 
and goats can both shed C. burnetii in subsequent 
pregnancies [59,60].
An elevated seroprevalence in domestic ruminants 
has been noted in areas with human outbreaks. In the 
outbreaks in Etropole (2002) and Botevgrad (2004) in 
Bulgaria, herd-level seroprevalence ranged from 11.6% 
to 33.0% (cattle), from 46.6% to 59.5% (sheep) and 
from 63.3 to almost 100% (goats). In contrast, median 
herd-level countrywide prevalence was 7.1 to 21.7% 
[23]. Of 26 sheep, goat and cattle flocks/herds located 
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within 5 km of an outbreak in Florac (2007) France, 11 
were enzyme-linked immunosorbent assay (ELISA)-
positive [25,61]. An increase in seroprevalence among 
ruminant herds in known areas of risk may assist in 
predicting outbreaks in humans.
Genetic differences of C. burnetii strains have been 
discussed as one reason for differing pathogenicities 
in guinea pigs and mice when infected with different 
isolates from domestic ruminants [23,62]. However, 
it is not clear whether there is a correlation between 
multilocus variable-number tandem repeat analysis 
(MLVA) types and virulence. The Dutch outbreak was 
the first outbreak where detailed investigations were 
conducted on the genotype of C. burnetii. A single 
MLVA type appeared responsible for the majority of 
the C. burnetii-related abortion on goat farms in the 
Netherlands [51]. Little is known of MLVA types from 
other outbreaks. The identified limited genetic diver-
sity in the Netherlands precludes investigation of local 
transmission pathways and molecular typing methods 
have to be developed further, including high-resolution 
genotyping based on whole genome sequencing, to 
match human, veterinary, and environmental samples. 
In the four countries under study, as elsewhere in the 
world [1,8], there is evidence of widespread exposure 
to C. burnetii in both the human and domestic ruminant 
populations. However, clinical cases of Q fever in peo-
ple are generally very rare. As reflected in this review, 
outbreaks are generally associated with a range of 
risk factors, including close contact between people 
and small ruminants, and events (such as abortions) 
leading to increased shedding of C. burnetii in these 
small ruminant populations. Other factors may also 
be important, but are not well understood. During the 
Dutch outbreak, for example, it was suggested that 
the human population in the Netherlands was more 
susceptible to disease because seroprevalence was 
low, the number of animals in the farms was high with 
consequent assumption of the amount of manure and 
lochia, with potential of human exposure. The change 
in management of animals from industrial-type housing 
to small private farms in Bulgaria was a hypothesis for 
the observed variation of within-herd prevalence over a 
period. However, it seems likely that C. burnetii infec-
tion can be maintained in a wide range of husbandry 
systems in all four countries. The Dutch outbreak 
developed in a geographic area without historic Q fever 
problems. This is different to the recognised pattern, in 
Bulgaria, France and Germany, of outbreak occurrence 
and re-occurrence in specific geographic localities. 
Although a windborne spread appears to have played 
an important role in the transmission of infection from 
animals to people, in all four countries. More work is 
needed to develop a systematic understanding of the 
risk factors involved and their interactions.
The control measures pursued by different countries 
were in general targeted at reducing human exposure 
and spill-over from animal populations to humans. In 
each of these countries, human cases have generally 
been linked to exposure to aerosols with high numbers 
of C. burnetii excreted during parturition by infected 
ruminants. During outbreaks in Bulgaria and France, 
strategies for prevention and control of Q fever in peo-
ple were designed, cognisant of the influence of spe-
cific conditions [32] on transmission of infection, such 
as dry weather, wind direction, and the location of 
human population at risk in a valley with hillside pas-
tures [26]. The main challenges on the control of the 
disease are linked to the sustainability of measures 
such as culling or reproduction bans but also the per-
sistence of infection in both animals and the environ-
ment. Furthermore there is limited data regarding the 
effectiveness of different control measures.
Measures that can be applied on-farm to reduce spill-
over from farm animals to humans are limited to vac-
cination and on-farm hygienic measures. There is 
evidence in support of vaccination being effective in 
preventing abortions in small ruminants and in reduc-
ing the shedding of C. burnetii [1,63], although it has 
been suggested that this must be sustained for at 
least several years [64,65]. Outbreak vaccination, i.e. 
vaccinating herds that already are infected [64,66] or 
otherwise under high infection pressure [65], are each 
believed to be less effective. The risk of Q fever out-
breaks and possibly other zoonotic diseases remains 
high in relatively small areas such as the province of 
Noord-Brabant in the Netherlands, with large popula-
tions of people (2.4 million) and animals (6.4 million). 
There remains uncertainty about the effectiveness of 
control measures other than vaccination. Farm hygienic 
measurements (such as manure sterilisation/compost-
ing and management, disinfection of the paths and 
ways to the pastures, indoor housing during lambing 
season, air-filter systems in housings and movement 
controls) are likely to have limited effectiveness in 
reducing infection risk. There is incomplete information 
about either C. burnetii survival times in manure and 
in the general environment, or the period during which 
surviving bacteria remain a threat for public health. 
Reports suppose a long lasting period of survival and 
infectivity, possibly up to two to three years or more 
[3,67]. Based on information from the Netherlands out-
break between 2007 and 2010, however, we did not 
find evidence for this. There was a rapid decrease in 
human cases in 2010, immediately following the last 
of the abortion storms that occurred in goats in 2009. 
Similarly, the various outbreaks in Germany and France 
were single events related to human exposure to small 
ruminants. In each situation, human cases were lim-
ited in time. The inevitable contamination of the envi-
ronment did not seem to cause an elevation of human 
cases for a longer period of time.
Concerning the Dutch Q fever outbreak during the 
period between 2007 and 2010, at least some facts 
can be ascertained. Seroprevalence among the general 
population increased from 2.4% before the first out-
break in 2007 to around 12% in the high incidence area 
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in 2009 (Table 2). During the same period, the num-
ber of notified acute Q fever patients decreased from 
2,354 in 2009 to 504 in 2010 [14]. Several veterinary 
measures were implemented in the Netherlands con-
currently, making it impossible to establish the rela-
tive contribution of each (vaccination, culling, on-farm 
hygienic measures, or other factors) to this decline in 
incidence. It should also be noted that the prevalence 
of C. burnetii in an infected herd usually declines over 
time even if no countermeasures are taken, probably 
caused by a ‘natural’ immunisation of susceptible ani-
mals (Table 1). However, meaningful scientific data are 
still missing. The development of a protective and safe 
vaccine for animals is strongly recommended.
Eradication of Q fever from a herd is not currently 
straightforward for a range of reasons, including 
chronic infection in a small number of animals (per-
sonal communication, R. Van den Brom, September 
2012), the presence of shedding, but test-negative, 
animals, and the potential for recurrent shedding of 
the agent [58,59,68]. Reduction of excretion has been 
reported using a phase 1 C. burnetii vaccine for animals, 
however, this could be affected by herd infection sta-
tus and the timing of vaccination [63-66]. To minimise 
human health risks, vaccination of animals may need 
to be conducted in combination with repeated testing, 
for example using a PCR on individual milk samples, 
and the culling of infected animals [69,55,57,64].
In each of the countries under investigation, sero-
prevalence measured at the individual animal level 
was lower than herd seroprevalence. In other words, 
in each herd only a relatively low number of animals 
seroconverted after contact with C. burnetii. This result 
is somewhat surprising, given the known high rate of 
infectivity of C. burnetii in ruminant populations (Table 
1). When C. burnetii is introduced on a farm with few 
pregnant animals (goats), seroconversion is expected 
mainly in these animals, following birth, because of 
the strong tropism of the pathogen for placenta tropho-
blasts [70], although C. burnetii is found everywhere in 
the surroundings. Low within-herd sero-prevalence is 
also seen with other infections where pathogens also 
may survive readily outside the host, such as para-
tuberculosis [71]. The role of differences in individual 
resistance and cell-mediated response should also be 
explored. 
Epidemiological studies on C. burnetii infection and 
Q fever in humans need to be interpreted with care, 
given differences in both the underlying epidemiologi-
cal conditions and the study designs used (including 
sample size, target groups, serological test, serologi-
cal cut-off and study purpose). The lack of standardi-
sation between studies was an important constraint 
in the current work. In most cases, studies have been 
conducted with biased sub-populations of people, 
including those with a known risk and elevated levels 
of C. burnetii in animal populations, such as for exam-
ple, people in the outbreak areas and with potentially 
compromised health. For these reasons, it can be diffi-
cult to draw meaningful conclusions about the underly-
ing seroprevalence of C. burnetii in people in these four 
countries. Further, observed differences over time are 
difficult to explain, such as the extremely high preva-
lence in a risk group in the Netherlands in the 1980s in 
comparison to the much lower prevalence in humans 
in outbreak area in recent years (February 2006–June 
2007) [2,72]. This latter observation may, in part at 
least, reflect a lack of specificity in earlier testing 
methods, which relied on in-house immunofluorescent 
assays and application of a low cut-off for positivity. 
However, seroprevalence in occupational risk groups in 
the 1980s and during the 2007 to 2010 outbreak in the 
Netherlands were comparable [14]. 
A number of conclusions can be drawn from this 
review of C. burnetii infection and Q fever in people 
and domestic ruminants in four countries in Europe. 
In all outbreaks, human contact with sheep and goats, 
rather than cattle, has been a consistent feature and 
the most likely source of C. burnetii infection. As yet, 
however, there is insufficient information to enable 
early prediction of large outbreaks of Q fever in peo-
ple. Mandatory notification of Q fever in humans is an 
important surveillance strategy, and has been recom-
mended previously [73], but is yet to be implemented 
in many countries in the EU [12]. Reporting of C. bur-
netii-related abortion cases in animals is compulsory 
in some countries [2,12], but interventions by authori-
ties are typically not initiated in sporadic cases. A more 
systematic use of such data for analysing the dynamics 
and seasonality of cases and to inform animal owners 
to take voluntary precautions should be considered. 
The cooperation and flow of information between vet-
erinary and medical professionals, and vice versa, 
is critical [2,73], and initiatives to build strong links 
between authorities involved in the monitoring and con-
trol of zoonoses similar to the Human Animal Infection 
Risk and Surveillance (HAIRS) group in England and 
Wales [74] are recommended. Much remains unclear 
about the transmission of C burnetii from animals to 
humans, about means for early detection of increased 
risk of outbreaks, the effectiveness of veterinary con-
trol measures, and about the best follow-up strategy in 
territories with repeated outbreaks over several years. 
Future research should focus on these topics.
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